FDA approves a new weight loss drug, Zepbound from Eli Lilly
CBSN
The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight loss as well.
While Mounjaro had already been used by some patients "off-label" for weight loss, the new FDA approval will allow the drugmaker to begin officially selling and marketing tirzepatide — branded as Zepbound — for weight loss too.
Zepbound will be available for patients in the U.S. by the end of the year, the drugmaker said.

At ski resorts across the West this winter, viral images showed chairlifts idling over brown terrain in places normally renowned for their frosty appeal. Iconic mountain towns like Aspen, Colorado, and Park City, Utah, were seen with shockingly bare slopes, as the region endured a historic snow drought that experts warn could bring water shortages and wildfires in the months ahead. In:












